India vs Trinidad and Tobago: Pneumococcal conjugate second or third-dose vaccines (PCVc)
India
97.0%
in 2025
Trinidad and Tobago
97.0%
in 2025
India rank
17th
Trinidad and Tobago rank
17th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- India
- Trinidad and Tobago
How they compare
India currently reports 97.0% against 97.0% in Trinidad and Tobago, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Trinidad and Tobago ahead.
India ranks 17th and Trinidad and Tobago ranks 17th of 194 countries.
Trinidad and Tobago has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | India | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 2.1% | 68.4% | 66.3% | Trinidad and Tobago |
| 2020s | 64.5% | 94.3% | 29.8% | Trinidad and Tobago |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), India or Trinidad and Tobago?
- India, at 97.0% against 97.0% in Trinidad and Tobago as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between India and Trinidad and Tobago?
- 0.0%, with India ahead.
- How many years of comparable data are there for India and Trinidad and Tobago?
- 18 years are reported by both, from 2008 to 2025.
- How do India and Trinidad and Tobago rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- India ranks 17th and Trinidad and Tobago ranks 17th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.